Gram‐Positive and Gram‐Negative Antibiotic Activity of Asymmetric and Monomeric Robenidine Analogues
作者:Cecilia C. Russell、Andrew Stevens、Hongfei Pi、Manouchehr Khazandi、Abiodun D. Ogunniyi、Kelly A. Young、Jennifer R. Baker、Siobhann N. McCluskey、Stephen W. Page、Darren J. Trott、Adam McCluskey
DOI:10.1002/cmdc.201800463
日期:2018.12.6
except with concomitant introduction of an imine C‐alkyl group. The activity of these analogues againstMRSA and VRE ranged from 8 μg mL−1 to inactive (MIC>128 μg mL−1) with the naphthyl and indole analogues. Gram‐negative activity was most promising with two compounds at 16 μg mL−1 against E. coli. Against P. aeruginosa, the highest activity observed was with MIC values of 32 μg mL−1 with another two analogues
罗非替丁的去对称化(1:N ',2-二((E)-4-氯苄叉)肼-1-羧酰亚胺肼)和亚胺烷基取代基的引入具有良好的抗生素活性。值得注意的是,两种类似物对耐万古霉素的肠球菌(VRE)的效力有所提高,其中一种的MIC为0.5μgmL -1。发现有五个类似物比铅1具有更强的效价。吲哚部分的引入导致针对甲氧西林抗性金黄色葡萄球菌(MRSA)的活性最强的robenidine类似物,MIC为1.0μgmL -1。亚胺C = NH等位基因(C = O / C = S)不活跃。单体类似物为16–64μgmL-1对MRSA和VRE有效。缺少末端酰肼NH部分的类似物在64μgmL -1下显示适度的革兰氏阴性活性。研究表明,在16–64μgmL -1下, 4-叔丁基类似物对革兰氏阳性和阴性菌株均具有活性。通常,除伴随引入亚胺C-烷基外,对芳香族基团的其他修饰耐受性差。这些类似物对MRSA和VRE的活性范围为8μgmL
1,4-Diacyl-3-acylamino-5-aryl-4,5-dihydro-1H-1,2,4-triazoles: Ring closure products of aromatic carbaldehyde (diaminomethylene) hydrazones with acylating agents
作者:Z. Gy�rgyde�k、W. Holzer、R. W. Kunz、A. Linden
DOI:10.1007/bf00807164
日期:——
Treatment of aromatic carbaldehyde (diaminomethylene)hydrazones 1 with hot acetic anhydride or benzoyl chloride affords 1,4-diacyl-3-acylamino-5-aryl-4,5-dihydro-1H-1,2,4-triazoles 2. In contrast, a new type of O,N-acetal with an 1,2,4-triazole substructure (3) is obtained from 4-pyridine-carbaldehyde (diaminomethylene)hydrazone (1i) by using a similar reaction procedure. The structures of all novel compounds were confirmed by spectroscopic data (H-1 and C-13 NMR, MS, IR); some representative compounds were also studied by X-ray analysis.
METHODS FOR TREATING PROTOZOAN INFECTIONS
申请人:Neoculi Pty Ltd
公开号:EP3188722A1
公开(公告)日:2017-07-12
[EN] METHODS FOR TREATING PROTOZOAN INFECTIONS<br/>[FR] MÉTHODES DE TRAITEMENT D'INFECTIONS À PROTOZOAIRES
申请人:NEOCULI PTY LTD
公开号:WO2016033635A1
公开(公告)日:2016-03-10
The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a protozoan infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a protozoan infection in a subject and to a medical device comprising the composition of the invention.
An unprecedented intramolecular to intermolecular mechanistic switch in 1,1-diaminoazines leading to differential product formation during the I<sub>2</sub>-induced tandem oxidative transformation
作者:Deepika Kathuria、Pankaj Gupta、Sumit S. Chourasiya、Subash C. Sahoo、Uwe Beifuss、Asit K. Chakraborti、Prasad V. Bharatam
DOI:10.1039/c9ob00610a
日期:——
been developed via tandem oxidative transformation of guanylhydrazones (in its preferentially existing azine tautomeric form) with distinct advantages such as wide substrate scope, use of substoichiometric amounts of iodine, no requirement of external oxidizing agents, base free reaction conditions, short reaction time and moderate to good yields. The role of silversalt in improving the yield and